DISCUSSION GLP1RAs have revolutionized obesity management, but their impact on GI motility introduces potential DDIs with orally administered medications, particularly those requiring precise dosing, such as anticoagulants and hormonal contraceptives
Tirzepatide is a novel dual GIP/GLP-1 receptor agonist and the Surmount 1 results showed an average 18% weight loss vs
Animal findings, human events, and causal conclusions should not be combined into a consumer warning list without context
Furthermore, patients with AP often receive medications (e.g., sedatives, antibiotics, and vasoactive agents) that can influence cytoskeletal organization and mitochondrial function, complicating the clinical applicability of strategies derived from reductionist models
For cash-pay buyers in 2026, compounded routes are typically cheapest
We present a novel case of a 73-year-old female who presented to the emergency department with acute appendicitis one week after being initiated on Tirzepatide
-1775582746855.png&w=3840&q=75)
